Biopharma | 05 May 2026
Zydus Lifesciences subsidiary faces Rs 9 million GST demand notice
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
India’s largest life sciences entrepreneurship competition opens applications for startups, innovators and student teams nationwide
Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
The cleanroom operates under stringent ISO Class 5 conditions, using ultrapure water and air systems
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
Subscribe To Our Newsletter & Stay Updated
